Breaking Down SG&A Expenses: Johnson & Johnson vs Alkermes plc

A Tale of Two Giants: SG&A Expenses in the Pharmaceutical Industry

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry leaders is crucial. Johnson & Johnson, a titan in healthcare, and Alkermes plc, a notable player in biopharmaceuticals, offer a fascinating comparison in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Johnson & Johnson's SG&A expenses have consistently dwarfed those of Alkermes, averaging around 42 times higher. However, Alkermes has shown a remarkable upward trend, with a 245% increase in SG&A expenses, reflecting its aggressive growth strategy. In contrast, Johnson & Johnson's expenses have remained relatively stable, with a slight decline of 8% over the same period. This financial narrative not only highlights the scale of operations but also underscores the strategic priorities of these two industry players.